secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001437749-24-012182
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports positive Phase 2 VISIONARY-MS LTE results for CNM-Au8 at AAN; shows repair and remyelination evidence
--------------------------------------------------------------------------------

- CNM-Au8 treatment up to 3 years showed significant vision improvement (low contrast letter acuity, p<0.001) and cognition (SDMT, p<0.001) vs original baseline.
- Physiologic markers of remyelination improved: mfVEP amplitude p<0.01, latency p=0.06.
- MRI measures of T2 lesion myelin water fraction and magnetization transfer ratio improved (p<0.05 and p=0.06), indicating structural repair.
- No significant safety findings; CNM-Au8 well-tolerated over long-term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924012182/0001437749-24-012182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924012182/clnn20240415_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-012182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer